Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Cell Davis, C. W., Jackson, K. J., McElroy, A. K., Halfmann, P. n., Huang, J. n., Chennareddy, C. n., Piper, A. E., Leung, Y. n., Albariño, C. G., Crozier, I. n., Ellebedy, A. H., Sidney, J. n., Sette, A. n., Yu, T. n., Nielsen, S. C., Goff, A. J., Spiropoulou, C. F., Saphire, E. O., Cavet, G. n., Kawaoka, Y. n., Mehta, A. K., Glass, P. J., Boyd, S. D., Ahmed, R. n. 2019

Abstract

Ebola virus (EBOV) remains a public health threat. We performed a longitudinal study of B cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection induced lasting EBOV-specific immunoglobulin G (IgG) antibodies, but their subclass composition changed over time, with IgG1 persisting, IgG3 rapidly declining, and IgG4 appearing late. Striking changes occurred in the immunoglobulin repertoire, with massive recruitment of naive B cells that subsequently underwent hypermutation. We characterized a large panel of EBOV glycoprotein-specific monoclonal antibodies (mAbs). Only a small subset of mAbs that bound glycoprotein by ELISA recognized cell-surface glycoprotein. However, this subset contained all neutralizing mAbs. Several mAbs protected against EBOV disease in animals, including one mAb that targeted an epitope under evolutionary selection during the 2014 outbreak. Convergent antibody evolution was seen across multiple donors, particularly among VH3-13 neutralizing antibodies specific for the GP1 core. Our study provides a benchmark for assessing EBOV vaccine-induced immunity.

View details for DOI 10.1016/j.cell.2019.04.036

View details for PubMedID 31104840